Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHGT7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Stelara 90 mg/ml syringes. The award, issued on November 26, 2025, is structured as a firm fixed-price delivery order with an ultimate completion date of December 18, 2025. This delivery order carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The order will be fulfilled at the vendor's Park Ridge location.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That master contract, awarded November 13, 2025, carries a $500 million ceiling and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V program authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. Stelara is a biologic immunosuppressant within DMS Pharmaceutical Group's established product portfolio of specialty pharmaceuticals and biologics supplied to military healthcare facilities.
Quick answers
Who was awarded contract SPE2DR26FHGT7?
SPE2DR26FHGT7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 26, 2025.
How much is contract SPE2DR26FHGT7 worth?
The government has obligated $16,584 on SPE2DR26FHGT7.
Is contract SPE2DR26FHGT7 an order under another contract?
Yes. SPE2DR26FHGT7 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGT7 competed?
The extent of competition for SPE2DR26FHGT7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award